Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA)

NFKBIA encodes IκBα, the principal inhibitor of the canonical NF-κB pathway.[2][3][5] IκBα binds to NF-κB transcription factors in the cytoplasm, preventing their nuclear translocation and transcriptional activity. Degradation or loss of IκBα permits NF-κB activation, promoting expression of genes involved in immune responses, inflammation, cell proliferation, and survival. Mutations or deletions of NFKBIA are linked to inflammation, immune deficiency, and various cancers, where deregulated NF-κB activity contributes to pathogenesis and therapy resistance.[2][3][1]

Other names

IκBαIkappaB-alphaNF-kappa-B inhibitor alphaIkBα

Stabilization or augmentation of IκBα activity to inhibit NF-κB activation Indirect effect: drugs preventing IκBα degradation retain NF-κB in the cytoplasm, blocking transcription of target genes